Systemic analysis of adverse drug events in patients with diabetes complicated by cataract treated with rizumab after surgery
Objective To investigate the occurrence of related adverse drug reactions(ADR)of rizumab injection in patients after diabetic cataract surgery.Methods A retrospective collection of medical records was conducted through an electronic medical record system and follow-up records of 75 patients receiving rizumab injection treatment after diabetic cataract surgery in Department of Ophthalmology of Xinjiang 474 Hospital from August 2021 to June 2023.The incidence of ADR,specific ADR and occurrence time were analyzed,and the differences in clinical characteristics were compared between the patients with ADR and those without.Results Among the 75 patients treated with rizumab injection,38(50.67%)experienced ADRs.There were no significant differences in gender composition(χ2=0.644,P=0.422)and age distribution(χ2=1.415,P=0.702)between the patients with ADR and those without.There were 35 patients(46.67%)with grade 1 and 2 ADRs,and 3(4.00%)with grade 3 and 4 ADRs.Among these,10 patients(13.33%)presented with ADRs affecting multiple systems,including 2 of cough,5 of nausea and 2 of allergic reactions(rash,urticaria,itching,and erythema)and 1 of arterial thromboembolism.The most common ADR was increased intraocular pressure in 19 patients,followed by conjunctival hemorrhage in 10.Grade 3 and 4 ADRs included 2 of retinal tear or detachment and 1 of arterial thromboembolism.For the 75 patients,the ADR incidence rate within 60 minutes was 30.67%(23/75).Among the 38 ADR cases,23 occurred within the first 60 minutes,accounting for 60.53%(23/38).All symptoms were alleviated after symptomatic treatment.Conclusion Approximately half of diabetic cataract patients experienced ADRs after receiving rizumab.Despite most ADR having grade 1 and 2 mild reactions,some patients develop severe grade 3 and 4 ADRs including retinal tear or detachment and arterial thromboembolism.This indicates that patient response should be strictly monitored in clinical practice and special attention should be paid to ADR within 60 minutes after medication.Symptomatic treatment can be effective in providing ADR relief and the prevention and management of severe ADR is still a key direction for future research.
Diabetic cataractRizumabAdverse drug reactionRational administrationProphylaxis
NETL
NSTL
万方数据
